Business Context and Reporting Period
This Form 8-K Current Report, dated January 7, 2026, covers the corporate name change of FibroGen, Inc. to Kyntra Bio, Inc. The amendment to the Certificate of Incorporation and Bylaws became effective at 4:30 p.m. Eastern Time on January 7, 2026.
Key Financial Metrics
This filing is a current report regarding a corporate name change and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Corporate Name: Changed from "FibroGen, Inc." to "Kyntra Bio, Inc."
- Trading Symbol: The common stock will trade under the new symbol "KYNB" starting at the market open on January 8, 2026, replacing the former symbol "FGEN."
- CUSIP Number: Remains unchanged at 31572Q881.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies related to operations. The document strictly addresses the administrative execution of the name change and the associated press release.
Investor Verification Checklist
- Verify the new ticker symbol "KYNB" on trading platforms effective January 8, 2026.
- Confirm that the CUSIP number (31572Q881) remains valid for the renamed entity.
- Review the attached press release (Exhibit 99.1) for strategic rationale behind the rebranding.
- Check subsequent filings for updated financial data under the new corporate name.